ClinVar Miner

Submissions for variant NM_003640.5(ELP1):c.2417A>G (p.Tyr806Cys)

gnomAD frequency: 0.00002  dbSNP: rs191464698
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Fulgent Genetics, Fulgent Genetics RCV002504390 SCV002815596 uncertain significance Medulloblastoma; Familial dysautonomia 2022-01-07 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV002542868 SCV003285327 uncertain significance not provided 2021-08-31 criteria provided, single submitter clinical testing This sequence change replaces tyrosine with cysteine at codon 806 of the ELP1 protein (p.Tyr806Cys). The tyrosine residue is weakly conserved and there is a large physicochemical difference between tyrosine and cysteine. This variant is present in population databases (rs191464698, ExAC 0.1%). This variant has not been reported in the literature in individuals affected with ELP1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004035445 SCV003855293 uncertain significance not specified 2023-02-16 criteria provided, single submitter clinical testing The p.Y806C variant (also known as c.2417A>G), located in coding exon 22 of the IKBKAP gene, results from an A to G substitution at nucleotide position 2417. The tyrosine at codon 806 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001277388 SCV001464336 uncertain significance Familial dysautonomia 2020-08-21 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.